2011
DOI: 10.5301/ejo.2011.6246
|View full text |Cite
|
Sign up to set email alerts
|

Regression of Serous Macular Detachment Due to Peripheral Exudative Hemorrhagic Chorioretinopathy following Intravitreal Bevacizumab

Abstract: Bevacizumab may be an effective treatment option for exudative macular detachment secondary to peripheral exudative hemorrhagic chorioretinopathy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(1 citation statement)
references
References 7 publications
0
0
1
Order By: Relevance
“…Anti-vascular endothelial growth factor treatment has yielded variable outcomes in terms of restoring visual acuity. [19][20][21] In the present study, antivascular endothelial growth factor treatment was not statistically associated with visual prognosis.…”
Section: Discussioncontrasting
confidence: 69%
“…Anti-vascular endothelial growth factor treatment has yielded variable outcomes in terms of restoring visual acuity. [19][20][21] In the present study, antivascular endothelial growth factor treatment was not statistically associated with visual prognosis.…”
Section: Discussioncontrasting
confidence: 69%